Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Core Viewpoint - Merck's two-drug HIV regimen has demonstrated comparable efficacy to Gilead's Biktarvy in Phase 3 trials and is currently under FDA review as the company anticipates the impact of Keytruda's patent expiration [1] Group 1: Drug Development - Merck's two-drug HIV regimen matches the performance of Gilead's Biktarvy in clinical trials [1] - The regimen is undergoing FDA review, indicating a potential for market entry [1] Group 2: Market Context - The development comes as Merck prepares for the impending patent cliff of its blockbuster drug Keytruda [1]